Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review
Hanbo Chen(Shenyang Agricultural University), Alexander V. Louie(London Health Sciences Centre), Suresh Senan(Amsterdam UMC Location VUmc), David A. Palma(Western University), Andrew Warner(London Health Sciences Centre), Gabriel Boldt(Cancer Care Ontario), Esther J. Nossent(Amsterdam UMC Location Vrije Universiteit Amsterdam)
International Journal of Radiation Oncology*Biology*Physics
March 15, 2017
Cited by 160
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.2k
Prophylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
|New England Journal of Medicine|2007|1.1k